Sebastian Nielsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sebastian Nielsen has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Christine Stabell Benn
Bandim Health Project, OPEN, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark; Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau; Danish Institute for Advanced Study, University of Southern Denmark, Odense, Denmark
26 shared publications - Peter Aaby
Southern Danish University
19 shared publications - Frederik Schaltz-Buchholzer
Bandim Health Project, INDEPTH Network , Bissau , Guinea-Bissau
10 shared publications - Ane Bærent Fisker
Bandim Health Project, Indepth Network Bissau Guinea‐Bissau
7 shared publications - Isaquel Silva
Bandim Health Project, Indepth network, Bissau, Guinea-Bissau
6 shared publications Amabelia Rodrigues
Bandim Hlth Project, Indepth Network, Bissau, Guinea Bissau
5 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by BMJ in BMJ Nutrition, Prevention & Health
Real-life effect of vitamin A supplementation campaigns on all-cause mortality: systematic review and meta-analysis
Introduction WHO recommends high-dose vitamin A supplementation (VAS) in vitamin A-deficient areas. Many countries deliver VAS in national campaigns. Based on randomised trials from the 1980s to 1990s, such campaigns are assumed to reduce all-cause mortality by 12–24%. There has been no analysis of the real-life effect of VAS campaigns on all-cause mortality.Methods We conducted a systematic review and a meta-analysis of the real-life effect of ‘VAS’ campaigns (defined as VAS±simultaneous deworming) on all-cause mortality. In November 2025 we searched PubMed, Embase and Web of Science for studies involving children <5 years of age that investigated VAS campaigns based on individual-level data and reported all-cause mortality. ROBINS-I was used to assess the methodological quality. Some campaigns provided VAS in combination with vaccines (oral polio vaccine (OPV) or measles vaccine). Meta-estimates were calculated as random (prioritised) and fixed effect estimates overall and by sex and age group.Results We identified five observational studies covering the period from 1999 to 2019, including a total of 163 996 children and 5449 deaths. Four studies were of moderate risk of bias, one of critical risk of bias. The meta-analysis showed no benefit of VAS campaigns on all-cause mortality, the random effect estimate being 1.07 (95% CI 0.82 to 1.38) (fixed effect estimate 1.17 (95% CI 1.03 to 1.32)). In males, the meta-estimate was 1.18 (95% CI 0.91 to 1.52) and in females 1.06 (95% CI 0.85 to 1.33). In comparison, the estimate for ‘OPV-only’ campaigns was 0.78 (95% CI 0.71 to 0.85) (p for same effect of ‘Any VAS’ vs ‘OPV-only’ campaigns <0.001).Conclusion The available low-certainty evidence did not support the assumption that current VAS campaigns reduce all-cause mortality. Contextual analyses of ‘OPV-only’ campaigns in the same settings showed beneficial effect. The effect of VAS may have changed over time. Contemporary randomised or robust quasi-experimental studies are needed to support the continued use of VAS campaigns.
- 9 October 2026
- Published by BMJ in BMJ Nutrition, Prevention & Health
Open AccessReal-life effect of vitamin A supplementation campaigns on all-cause mortality: systematic review and meta-analysis
Introduction WHO recommends high-dose vitamin A supplementation (VAS) in vitamin A-deficient areas. Many countries deliver VAS in national campaigns. Based on randomised trials from the 1980s to 1990s, such campaigns are assumed to reduce all-cause mortality by 12–24%. There has been no analysis of the real-life effect of VAS campaigns on all-cause mortality.Methods We conducted a systematic review and a meta-analysis of the real-life effect of ‘VAS’ campaigns (defined as VAS±simultaneous deworming) on all-cause mortality. In November 2025 we searched PubMed, Embase and Web of Science for studies involving children <5 years of age that investigated VAS campaigns based on individual-level data and reported all-cause mortality. ROBINS-I was used to assess the methodological quality. Some campaigns provided VAS in combination with vaccines (oral polio vaccine (OPV) or measles vaccine). Meta-estimates were calculated as random (prioritised) and fixed effect estimates overall and by sex and age group.Results We identified five observational studies covering the period from 1999 to 2019, including a total of 163 996 children and 5449 deaths. Four studies were of moderate risk of bias, one of critical risk of bias. The meta-analysis showed no benefit of VAS campaigns on all-cause mortality, the random effect estimate being 1.07 (95% CI 0.82 to 1.38) (fixed effect estimate 1.17 (95% CI 1.03 to 1.32)). In males, the meta-estimate was 1.18 (95% CI 0.91 to 1.52) and in females 1.06 (95% CI 0.85 to 1.33). In comparison, the estimate for ‘OPV-only’ campaigns was 0.78 (95% CI 0.71 to 0.85) (p for same effect of ‘Any VAS’ vs ‘OPV-only’ campaigns <0.001).Conclusion The available low-certainty evidence did not support the assumption that current VAS campaigns reduce all-cause mortality. Contextual analyses of ‘OPV-only’ campaigns in the same settings showed beneficial effect. The effect of VAS may have changed over time. Contemporary randomised or robust quasi-experimental studies are needed to support the continued use of VAS campaigns.
- 4 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e1131-e1132
Misleading Comments About the Impact of Early Bacillus Calmette-Guerin Vaccination on Neonatal and Infant Mortality
- 4 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (5) , e1131-e1132
Misleading Comments About the Impact of Early Bacillus Calmette-Guerin Vaccination on Neonatal and Infant Mortality
- Open Access
The effect of BCG vaccination on adult mortality during the COVID-19 pandemic: a meta-analysis of randomised controlled trials
Objectives: Bacillus Calmette-Guérin (BCG), similar to some other live vaccines, may offer partial protection against unrelated infections. During the COVID-19 pandemic, several trials tested whether BCG provides protection against COVID-19. Design: Meta-analysis of randomised placebo-controlled trials which provided mortality data. Setting: High-income settings as well as low- and middle-income settings (LMICs). Participants: Trial populations were healthcare workers (HCW) or individuals of older age, followed for 6-12 months. Interventions: BCG vaccine versus placebo. Main outcome measure: Overall mortality and COVID-19 mortality. Results: Nine of the 15 RCTs reported at least one death. Trial populations were healthcare workers (4 RCTs) or individuals of older age (5 RCTs), in Europe (5 RCTs) or LMICs (4 RCTs) with a total of 8,169 participants randomly allocated to BCG (18 deaths) and 8,176 to placebo (37 deaths). In a meta-analysis, receiving BCG vs placebo was associated with a 51% (95% CI: 15 to72%) reduction in all-cause mortality. The all-cause mortality RRR was 78% (−3 to 95%) in HCWs (Europe and LMICs) and 43% (95% CI: −6 to 69%) in the elderly. It was 37% (95 CI: −15 to 66%) in Europe and 90% (95% CI: 22 to 99%) in LMICs. The relative reduction of deaths (6 BCG; 12 placebo) from COVID-19 was 50% (95 CI: −33 to 81). Conclusions: BCG may have reduced all-cause mortality in the context of the COVID-19 pandemic.
Open AccessThe effect of BCG vaccination on adult mortality during the COVID-19 pandemic: a meta-analysis of randomised controlled trials
Objectives: Bacillus Calmette-Guérin (BCG), similar to some other live vaccines, may offer partial protection against unrelated infections. During the COVID-19 pandemic, several trials tested whether BCG provides protection against COVID-19. Design: Meta-analysis of randomised placebo-controlled trials which provided mortality data. Setting: High-income settings as well as low- and middle-income settings (LMICs). Participants: Trial populations were healthcare workers (HCW) or individuals of older age, followed for 6-12 months. Interventions: BCG vaccine versus placebo. Main outcome measure: Overall mortality and COVID-19 mortality. Results: Nine of the 15 RCTs reported at least one death. Trial populations were healthcare workers (4 RCTs) or individuals of older age (5 RCTs), in Europe (5 RCTs) or LMICs (4 RCTs) with a total of 8,169 participants randomly allocated to BCG (18 deaths) and 8,176 to placebo (37 deaths). In a meta-analysis, receiving BCG vs placebo was associated with a 51% (95% CI: 15 to72%) reduction in all-cause mortality. The all-cause mortality RRR was 78% (−3 to 95%) in HCWs (Europe and LMICs) and 43% (95% CI: −6 to 69%) in the elderly. It was 37% (95 CI: −15 to 66%) in Europe and 90% (95% CI: 22 to 99%) in LMICs. The relative reduction of deaths (6 BCG; 12 placebo) from COVID-19 was 50% (95 CI: −33 to 81). Conclusions: BCG may have reduced all-cause mortality in the context of the COVID-19 pandemic.
- Open Access
Randomised trial of not providing booster diphtheria-tetanus-pertussis (DTP) vaccination after measles vaccination and child survival: A failed trial
Background: In low-income settings, WHO recommended a booster-dose of DTP (DTP4) and OPV (OPV4) at 18 months of age. Previous studies found DTP after MV to be associated with higher female mortality. We conducted a randomised trial (RCTs) in Guinea-Bissau, in which children from 18 months of age were randomised to receive DTP4+OPV4 vs OPV4-only to assess the impact on survival and hospitalisations, overall and by sex. Methods: The trial was conducted from 2005-2012. Children were randomised and followed from 18 months to 4 years of age. Hospitalisations were captured through a surveillance system at the main paediatric ward, and deaths were detected through a demographic surveillance system in the study area and through yearly home visits to the study participants. Data was analysed in Cox proportional hazards models. The RCT aimed to enrol 6,000 children based on an expected annual mortality rate of 3%. During the trial period many new interventions, including many national health campaigns, were carried out. Results: The trial enrolled 5,918 children of which 96% (5,673) were included in the analysis. Annual non-accidental mortality rate was 0.56%, 81% lower than the expected rate. There was no difference in mortality between the randomisation groups. With 30 and 35 deaths, the hazard ratio (HR) for DTP4+OPV4 vs OPV4-only was 0.84 (95% CI=0.52-1.37); 0.86 (0.42-1.77) in males and 0.82 (0.42-1.60) in females. The HR for hospitalisations was 0.90 (0.77-1.06); 0.87 (0.70-1.09) in males; 0.94 (0.74-1.20) in females). Conclusion: The study found no negative effect of DTP4 and no sex-differential effect of DTP4, but it was strongly underpowered. Furthermore, due to the large number of health interventions, not envisioned at the initiation of the trial, a limited part of the follow-up was a comparison between DTP4+OPV4 vs OPV4 as the most recent vaccinations.
Open AccessRandomised trial of not providing booster diphtheria-tetanus-pertussis (DTP) vaccination after measles vaccination and child survival: A failed trial
Background: In low-income settings, WHO recommended a booster-dose of DTP (DTP4) and OPV (OPV4) at 18 months of age. Previous studies found DTP after MV to be associated with higher female mortality. We conducted a randomised trial (RCTs) in Guinea-Bissau, in which children from 18 months of age were randomised to receive DTP4+OPV4 vs OPV4-only to assess the impact on survival and hospitalisations, overall and by sex. Methods: The trial was conducted from 2005-2012. Children were randomised and followed from 18 months to 4 years of age. Hospitalisations were captured through a surveillance system at the main paediatric ward, and deaths were detected through a demographic surveillance system in the study area and through yearly home visits to the study participants. Data was analysed in Cox proportional hazards models. The RCT aimed to enrol 6,000 children based on an expected annual mortality rate of 3%. During the trial period many new interventions, including many national health campaigns, were carried out. Results: The trial enrolled 5,918 children of which 96% (5,673) were included in the analysis. Annual non-accidental mortality rate was 0.56%, 81% lower than the expected rate. There was no difference in mortality between the randomisation groups. With 30 and 35 deaths, the hazard ratio (HR) for DTP4+OPV4 vs OPV4-only was 0.84 (95% CI=0.52-1.37); 0.86 (0.42-1.77) in males and 0.82 (0.42-1.60) in females. The HR for hospitalisations was 0.90 (0.77-1.06); 0.87 (0.70-1.09) in males; 0.94 (0.74-1.20) in females). Conclusion: The study found no negative effect of DTP4 and no sex-differential effect of DTP4, but it was strongly underpowered. Furthermore, due to the large number of health interventions, not envisioned at the initiation of the trial, a limited part of the follow-up was a comparison between DTP4+OPV4 vs OPV4 as the most recent vaccinations.
- Open Access
- 1 October 2025
- Published by MDPI AG in Preprints.org
Beneficial Non‐Specific Effects of Measles Vaccine: Fact or Fiction?
Background: A recent Systematic Review claimed that randomised controlled trials (RCTs) showed that there are no beneficial non-specific effects (NSEs) of measles vaccine (MV); i.e. effects not explained by prevention of measles infection. The claim contradicts previous meta-analyses. Methods: We examined the reasons for these contradictory views. For ethical reasons there are few RCTs of MV in low-income countries (LIC), mainly trials of standard-titre-measles vaccine (STMV) vs high-titre-measles-vaccine (HTMV) in the 1980-90s and trials of two-dose vs one-dose of STMV in the 2000s. We reanalysed the RCTs taking the effect of subsequent vaccinations into consideration. Results: The PLOS One review claimed that there are no NSEs since the RCTs of a two-dose strategy gave a meta-estimate of 1.0. The negative effect of HTMV was considered a specific effect due to an excessive vaccine dose. In our reanalysis, one dose of STMV/HTMV versus control vaccine in the age interval 4-9 months, before controls received routine MV, was associated with a mortality ratio of 0.61 (0.37-0.99). After 9 months, STMV compared with HTMV-followed-by-a-non-live vaccine had a MR of 0.72 (0.55-0.95), significantly better for females than males. Discussion: The viral dose explanation of HTMV is not valid as it did not explain why the negative effects only applied to females. The review authors did not take into consideration that most RCTs in LIC experience interactions with vaccine campaigns and subsequent routine vaccinations. When these interactions are taken into consideration, the very RCTs selected by the PLOS One review do in fact show beneficial NSEs of MV. Conclusion: NSEs are still critical factors to take into consideration in planning of vaccination policy.
- 1 October 2025
- Published by MDPI AG in Preprints.org
Open AccessBeneficial Non‐Specific Effects of Measles Vaccine: Fact or Fiction?
Background: A recent Systematic Review claimed that randomised controlled trials (RCTs) showed that there are no beneficial non-specific effects (NSEs) of measles vaccine (MV); i.e. effects not explained by prevention of measles infection. The claim contradicts previous meta-analyses. Methods: We examined the reasons for these contradictory views. For ethical reasons there are few RCTs of MV in low-income countries (LIC), mainly trials of standard-titre-measles vaccine (STMV) vs high-titre-measles-vaccine (HTMV) in the 1980-90s and trials of two-dose vs one-dose of STMV in the 2000s. We reanalysed the RCTs taking the effect of subsequent vaccinations into consideration. Results: The PLOS One review claimed that there are no NSEs since the RCTs of a two-dose strategy gave a meta-estimate of 1.0. The negative effect of HTMV was considered a specific effect due to an excessive vaccine dose. In our reanalysis, one dose of STMV/HTMV versus control vaccine in the age interval 4-9 months, before controls received routine MV, was associated with a mortality ratio of 0.61 (0.37-0.99). After 9 months, STMV compared with HTMV-followed-by-a-non-live vaccine had a MR of 0.72 (0.55-0.95), significantly better for females than males. Discussion: The viral dose explanation of HTMV is not valid as it did not explain why the negative effects only applied to females. The review authors did not take into consideration that most RCTs in LIC experience interactions with vaccine campaigns and subsequent routine vaccinations. When these interactions are taken into consideration, the very RCTs selected by the PLOS One review do in fact show beneficial NSEs of MV. Conclusion: NSEs are still critical factors to take into consideration in planning of vaccination policy.
- 20 November 2024
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
Randomized trial of BCG in healthcare workers to reduce absenteeism during the COVID-19 pandemic in sub-Saharan Africa
Background: We tested whether providing BCG vaccine to healthcare workers (HCWs) could reduce non-planned absenteeism and thereby reduce the potential impact of the COVID-19 pandemic on healthcare systems in Africa. Methods: We conducted a multicenter, single-blinded, placebo-controlled randomized trial in Guinea-Bissau and Mozambique between December 2020 and June 2022. Participants were randomized 1:1 to BCG vaccine or placebo (saline) and followed by biweekly telephone calls for 6 mo. The incidence of unplanned absenteeism due to illness was analyzed using Bayesian negative binomial regression yielding relative RRs. Secondary outcomes included infectious disease episodes, COVID-19 infection and all-cause hospitalizations. Results: We enrolled 668 HCWs (Guinea-Bissau, n=503; Mozambique, n=165). The RR for absenteeism of BCG vs placebo was 1.29 (0.81 to 1.94) with comparable effects by country. No protection against infectious disease episodes (HR=1.18 [0.97 to 1.45]) or COVID-19 infection (HR=1.19 [0.80 to 1.75]) was observed. Two trial deaths (1 BCG, 1 control) were registered and nine admissions (3 BCG, 6 control), the all-cause admission HR being 0.51 (0.13 to 2.03). Conclusions: With 64% of the planned sample size and unplanned absenteeism rates lower than expected, BCG did not reduce self-reported absenteeism due to illness. Rather, BCG tended to increase the risk of self-reported absenteeism, infectious disease episodes and COVID-19 infections. Short summary: This was a randomized control trial assessing non-specific effects of BCG vaccination in healthcare workers. There was no beneficial effect on self-reported absenteeism due to illness within 6 mo of follow-up during the COVID-19 pandemic, but a trend towards fewer all-cause hospital admissions.
- 20 November 2024
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
Randomized trial of BCG in healthcare workers to reduce absenteeism during the COVID-19 pandemic in sub-Saharan Africa
Background: We tested whether providing BCG vaccine to healthcare workers (HCWs) could reduce non-planned absenteeism and thereby reduce the potential impact of the COVID-19 pandemic on healthcare systems in Africa. Methods: We conducted a multicenter, single-blinded, placebo-controlled randomized trial in Guinea-Bissau and Mozambique between December 2020 and June 2022. Participants were randomized 1:1 to BCG vaccine or placebo (saline) and followed by biweekly telephone calls for 6 mo. The incidence of unplanned absenteeism due to illness was analyzed using Bayesian negative binomial regression yielding relative RRs. Secondary outcomes included infectious disease episodes, COVID-19 infection and all-cause hospitalizations. Results: We enrolled 668 HCWs (Guinea-Bissau, n=503; Mozambique, n=165). The RR for absenteeism of BCG vs placebo was 1.29 (0.81 to 1.94) with comparable effects by country. No protection against infectious disease episodes (HR=1.18 [0.97 to 1.45]) or COVID-19 infection (HR=1.19 [0.80 to 1.75]) was observed. Two trial deaths (1 BCG, 1 control) were registered and nine admissions (3 BCG, 6 control), the all-cause admission HR being 0.51 (0.13 to 2.03). Conclusions: With 64% of the planned sample size and unplanned absenteeism rates lower than expected, BCG did not reduce self-reported absenteeism due to illness. Rather, BCG tended to increase the risk of self-reported absenteeism, infectious disease episodes and COVID-19 infections. Short summary: This was a randomized control trial assessing non-specific effects of BCG vaccination in healthcare workers. There was no beneficial effect on self-reported absenteeism due to illness within 6 mo of follow-up during the COVID-19 pandemic, but a trend towards fewer all-cause hospital admissions.
- Open Access
- 18 November 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100588
The importance of quality of health campaign information for outcome evaluation. A case study from Guinea-Bissau and Bangladesh
- 18 November 2024
- Published by Elsevier in Vaccine: X
- Vol. 21, 100588
Open AccessThe importance of quality of health campaign information for outcome evaluation. A case study from Guinea-Bissau and Bangladesh
- Open Access
- 17 October 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (6) , 106319
Evaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: A randomised clinical trial
- 17 October 2024
- Published by Elsevier in Journal of Infection
- Vol. 89 (6) , 106319
Open AccessEvaluating the effect of BCG vaccination for non-specific protection from infection in senior citizens during the COVID-19 pandemic: A randomised clinical trial
- Open Access
- 30 August 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 148, 107224
Contradictory mortality results in early 2-dose measles vaccine trials: interactions with oral polio vaccine may explain differences
- 30 August 2024
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 148, 107224
Open AccessContradictory mortality results in early 2-dose measles vaccine trials: interactions with oral polio vaccine may explain differences
- 17 May 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (4) , 995-1003
Maternal Bacille Calmette-Guérin Scars and Mortality Risk for Male and Female Newborns: Observational Study From Guinea-Bissau
Background: Maternal priming with bacille Calmette-Guérin (BCG) has been associated with reduced mortality in male offspring. We investigated this association in a cohort of healthy BCG-vaccinated neonates. Methods: This observational study within a randomized controlled trial comparing different BCG strains was conducted in Guinea-Bissau from 2017 to 2020. As part of trial inclusion procedures, on the day of discharge from the maternity ward, maternal BCG scar status was evaluated by visual inspection, followed by offspring BCG and polio vaccination. Through mortality data collected at telephone interviews at 6 weeks and 6 months of age, we assessed all-cause mortality risk in Cox proportional hazards models adjusted for maternal schooling and BCG strain, providing adjusted mortality rate ratios (aMRRs). Results: In total, 64% (11 070/17 275) of mothers had a BCG scar, which was not associated with admission risk, admission severity, or all-cause mortality for females and the overall sample. By 6 months of age, the mortality rate (MR) was 4.1 (200 deaths/4919 person-years) for the maternal BCG scar cohort and 5.2 (139/2661) for no maternal scar (aMRR, 0.86; 95% Confidence Interval [CI], .69–1.06). In males, 6-month MRs were 4.3 (109 deaths/2531 person-years) for maternal BCG scar vs 6.3 (87/1376) for no scar (aMRR, 0.74; 95% CI, .56–.99). In females, 6-month MRs were 3.8 (91 deaths/2388 person-years) vs 4.0 (52/1286), respectively (aMRR, 1.04; 95% CI, .74–1.47; for interaction with sex, P = .16). Conclusions: While we cannot rule out an association in females, being born to a mother with a BCG scar reduced the risk of death during early infancy for BCG-vaccinated males, reproducing findings from previous studies.
- 17 May 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (4) , 995-1003
Maternal Bacille Calmette-Guérin Scars and Mortality Risk for Male and Female Newborns: Observational Study From Guinea-Bissau
Background: Maternal priming with bacille Calmette-Guérin (BCG) has been associated with reduced mortality in male offspring. We investigated this association in a cohort of healthy BCG-vaccinated neonates. Methods: This observational study within a randomized controlled trial comparing different BCG strains was conducted in Guinea-Bissau from 2017 to 2020. As part of trial inclusion procedures, on the day of discharge from the maternity ward, maternal BCG scar status was evaluated by visual inspection, followed by offspring BCG and polio vaccination. Through mortality data collected at telephone interviews at 6 weeks and 6 months of age, we assessed all-cause mortality risk in Cox proportional hazards models adjusted for maternal schooling and BCG strain, providing adjusted mortality rate ratios (aMRRs). Results: In total, 64% (11 070/17 275) of mothers had a BCG scar, which was not associated with admission risk, admission severity, or all-cause mortality for females and the overall sample. By 6 months of age, the mortality rate (MR) was 4.1 (200 deaths/4919 person-years) for the maternal BCG scar cohort and 5.2 (139/2661) for no maternal scar (aMRR, 0.86; 95% Confidence Interval [CI], .69–1.06). In males, 6-month MRs were 4.3 (109 deaths/2531 person-years) for maternal BCG scar vs 6.3 (87/1376) for no scar (aMRR, 0.74; 95% CI, .56–.99). In females, 6-month MRs were 3.8 (91 deaths/2388 person-years) vs 4.0 (52/1286), respectively (aMRR, 1.04; 95% CI, .74–1.47; for interaction with sex, P = .16). Conclusions: While we cannot rule out an association in females, being born to a mother with a BCG scar reduced the risk of death during early infancy for BCG-vaccinated males, reproducing findings from previous studies.